Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

Home

LNSR

L

LENSAR, Inc. (LNSR)

NCM – Real vaqt narxi. Valyuta: USD

6.07

+0.55 (9.96%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

6.12

+0.05 (0.82%)

Bozordan keyin: Mar 27, 2026, 7:51 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

LENSAR Stock Plunges—Alcon Scraps Merger After Prolonged Regulatory Review

LENSAR Stock Plunges—Alcon Scraps Merger After Prolonged Regulatory Review

In March 2025, Alcon agreed to acquire the laser solutions company for $14.00 per share for an aggregate implied value of approximately $356 million.

LENSAR® Announces Termination of Merger Agreement with Alcon Research, LLC

LENSAR® Announces Termination of Merger Agreement with Alcon Research, LLC

ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, announced that it reached an agreement with Alcon Research, LLC (“Alcon”) to terminate the merger agreement between the parties.

LENSAR® Provides Update on Pending Acquisition by Alcon

LENSAR® Provides Update on Pending Acquisition by Alcon

ORLANDO, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today provided an update on the status of its pending acquisition by Alcon Research, LLC (“Alcon”).

LENSAR® Reports Third Quarter 2025 Results and Provides Business Update

LENSAR® Reports Third Quarter 2025 Results and Provides Business Update

18 ALLY Robotic Cataract Laser Systems ® (“ALLY Systems”) placed in 3Q 2025; Backlog of 18 ALLY Systems pending installation as of September 30, 2025 ALLY installed base grew 77% and total laser installed base grew 20% over 3Q 2024 ORLANDO, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended September 30, 2025 and provided an update on key operational initiatives.

Lensar (LNSR) Q2 Revenue Rises 10%

Lensar (LNSR) Q2 Revenue Rises 10%

Lensar (LNSR) Q2 Revenue Rises 10%

LENSAR Reports Second Quarter 2025 Results and Provides Business Update

LENSAR Reports Second Quarter 2025 Results and Provides Business Update

18 ALLY Robotic Cataract Laser Systems™ (“ALLY Systems”) placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025

Videolar

No Data

There is no data to display

Press-relizlar

LENSAR® Announces Termination of Merger Agreement with Alcon Research, LLC

LENSAR® Announces Termination of Merger Agreement with Alcon Research, LLC

ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, announced that it reached an agreement with Alcon Research, LLC (“Alcon”) to terminate the merger agreement between the parties.

LENSAR® Provides Update on Pending Acquisition by Alcon

LENSAR® Provides Update on Pending Acquisition by Alcon

ORLANDO, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today provided an update on the status of its pending acquisition by Alcon Research, LLC (“Alcon”).

LENSAR® Reports Third Quarter 2025 Results and Provides Business Update

LENSAR® Reports Third Quarter 2025 Results and Provides Business Update

18 ALLY Robotic Cataract Laser Systems ® (“ALLY Systems”) placed in 3Q 2025; Backlog of 18 ALLY Systems pending installation as of September 30, 2025 ALLY installed base grew 77% and total laser installed base grew 20% over 3Q 2024 ORLANDO, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended September 30, 2025 and provided an update on key operational initiatives.

LENSAR Reports Second Quarter 2025 Results and Provides Business Update

LENSAR Reports Second Quarter 2025 Results and Provides Business Update

18 ALLY Robotic Cataract Laser Systems™ (“ALLY Systems”) placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025